Parabiago, Italy

Fabio Gasparri

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fabio Gasparri: Innovator in Protein Kinase Inhibitors

Introduction

Fabio Gasparri is a notable inventor based in Parabiago, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target protein kinase activity. His work is crucial in the ongoing fight against diseases such as cancer.

Latest Patents

Gasparri holds a patent for "Bicyclic pyrazoles as protein kinase inhibitors." This patent includes 3,4-diaryl-bicyclicpyrazole derivatives, which are defined in the specification, along with their pharmaceutically acceptable salts. The patent outlines the process for their preparation and the pharmaceutical compositions that comprise them. The compounds developed by Gasparri may be beneficial in therapeutic applications, particularly for treating diseases associated with disregulated protein kinase activity.

Career Highlights

Gasparri's career is marked by his dedication to research and innovation in the pharmaceutical industry. He is currently associated with Nerviano Medical Sciences S.r.l., where he continues to explore new avenues for drug development. His work has the potential to impact many lives by providing new treatment options for serious health conditions.

Collaborations

Gasparri collaborates with talented professionals in his field, including Maurizio Pulici and Chiara Marchionni. These partnerships enhance the research and development process, fostering an environment of innovation and creativity.

Conclusion

Fabio Gasparri is a prominent figure in the realm of pharmaceutical innovation, particularly in the development of protein kinase inhibitors. His contributions are paving the way for new therapeutic solutions in the treatment of cancer and other diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…